Cargando…

A novel in vitro three-dimensional retinoblastoma model for evaluating chemotherapeutic drugs

PURPOSE: Novel strategies are being applied for creating better in vitro models that simulate in vivo conditions for testing the efficacy of anticancer drugs. In the present study we developed surface-engineered, large and porous, biodegradable, polymeric microparticles as a scaffold for three dimen...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitra, Moutushy, Mohanty, Chandana, Harilal, Anju, Maheswari, Uma K., Sahoo, Sanjeeb Kumar, Krishnakumar, Subramanian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Vision 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369889/
https://www.ncbi.nlm.nih.gov/pubmed/22690114
_version_ 1782235101771333632
author Mitra, Moutushy
Mohanty, Chandana
Harilal, Anju
Maheswari, Uma K.
Sahoo, Sanjeeb Kumar
Krishnakumar, Subramanian
author_facet Mitra, Moutushy
Mohanty, Chandana
Harilal, Anju
Maheswari, Uma K.
Sahoo, Sanjeeb Kumar
Krishnakumar, Subramanian
author_sort Mitra, Moutushy
collection PubMed
description PURPOSE: Novel strategies are being applied for creating better in vitro models that simulate in vivo conditions for testing the efficacy of anticancer drugs. In the present study we developed surface-engineered, large and porous, biodegradable, polymeric microparticles as a scaffold for three dimensional (3-D) growth of a Y79 retinoblastoma (RB) cell line. We evaluated the effect of three anticancer drugs in naïve and nanoparticle-loaded forms on a 3-D versus a two-dimensional (2-D) model. We also studied the influence of microparticles on extracellular matrix (ECM) synthesis and whole genome miRNA-gene expression profiling to identify 3D-responsive genes that are implicated in oncogenesis in RB cells. METHODS: Poly(D,L)-lactide-co-glycolide (PLGA) microparticles were prepared by the solvent evaporation method. RB cell line Y79 was grown alone or with PLGA–gelatin microparticles. Antiproliferative activity, drug diffusion, and cellular uptake were studied by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole (MTT) assay, fluorescent microscope, and flow cytometry. Extra cellular matrix (ECM) synthesis was observed by collagenase assay and whole genome miRNA-microarray profiling by using an Agilent chip. RESULTS: With optimized composition of microparticles and cell culture conditions, an eightfold increase from the seeding density was achieved in 5 days of culture. The antiproliferative effect of the drugs in the 3-D model was significantly lower than in the 2-D suspension, which was evident from the 4.5 to 21.8 fold differences in their IC(50) values. Using doxorubicin, the flow cytometry data demonstrated a 4.4 fold lower drug accumulation in the cells grown in the 3-D model at 4 h. The collagen content of the cells grown in the 3-D model was 2.3 fold greater than that of the cells grown in the 2-D model, suggesting greater synthesis of the extracellular matrix in the 3-D model as the extracellular matrix acted as a barrier to drug diffusion. The microarray and miRNA analysis showed changes in several genes and miRNA expression in cells grown in the 3-D model, which could also influence the environment and drug effects. CONCLUSIONS: Our 3-D retinoblastoma model could be used in developing effective drugs based on a better understanding of the role of chemical, biologic, and physical parameters in the process of drug diffusion through the tumor mass, drug retention, and therapeutic outcome.
format Online
Article
Text
id pubmed-3369889
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Molecular Vision
record_format MEDLINE/PubMed
spelling pubmed-33698892012-06-11 A novel in vitro three-dimensional retinoblastoma model for evaluating chemotherapeutic drugs Mitra, Moutushy Mohanty, Chandana Harilal, Anju Maheswari, Uma K. Sahoo, Sanjeeb Kumar Krishnakumar, Subramanian Mol Vis Research Article PURPOSE: Novel strategies are being applied for creating better in vitro models that simulate in vivo conditions for testing the efficacy of anticancer drugs. In the present study we developed surface-engineered, large and porous, biodegradable, polymeric microparticles as a scaffold for three dimensional (3-D) growth of a Y79 retinoblastoma (RB) cell line. We evaluated the effect of three anticancer drugs in naïve and nanoparticle-loaded forms on a 3-D versus a two-dimensional (2-D) model. We also studied the influence of microparticles on extracellular matrix (ECM) synthesis and whole genome miRNA-gene expression profiling to identify 3D-responsive genes that are implicated in oncogenesis in RB cells. METHODS: Poly(D,L)-lactide-co-glycolide (PLGA) microparticles were prepared by the solvent evaporation method. RB cell line Y79 was grown alone or with PLGA–gelatin microparticles. Antiproliferative activity, drug diffusion, and cellular uptake were studied by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole (MTT) assay, fluorescent microscope, and flow cytometry. Extra cellular matrix (ECM) synthesis was observed by collagenase assay and whole genome miRNA-microarray profiling by using an Agilent chip. RESULTS: With optimized composition of microparticles and cell culture conditions, an eightfold increase from the seeding density was achieved in 5 days of culture. The antiproliferative effect of the drugs in the 3-D model was significantly lower than in the 2-D suspension, which was evident from the 4.5 to 21.8 fold differences in their IC(50) values. Using doxorubicin, the flow cytometry data demonstrated a 4.4 fold lower drug accumulation in the cells grown in the 3-D model at 4 h. The collagen content of the cells grown in the 3-D model was 2.3 fold greater than that of the cells grown in the 2-D model, suggesting greater synthesis of the extracellular matrix in the 3-D model as the extracellular matrix acted as a barrier to drug diffusion. The microarray and miRNA analysis showed changes in several genes and miRNA expression in cells grown in the 3-D model, which could also influence the environment and drug effects. CONCLUSIONS: Our 3-D retinoblastoma model could be used in developing effective drugs based on a better understanding of the role of chemical, biologic, and physical parameters in the process of drug diffusion through the tumor mass, drug retention, and therapeutic outcome. Molecular Vision 2012-05-31 /pmc/articles/PMC3369889/ /pubmed/22690114 Text en Copyright © 2012 Molecular Vision. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Mitra, Moutushy
Mohanty, Chandana
Harilal, Anju
Maheswari, Uma K.
Sahoo, Sanjeeb Kumar
Krishnakumar, Subramanian
A novel in vitro three-dimensional retinoblastoma model for evaluating chemotherapeutic drugs
title A novel in vitro three-dimensional retinoblastoma model for evaluating chemotherapeutic drugs
title_full A novel in vitro three-dimensional retinoblastoma model for evaluating chemotherapeutic drugs
title_fullStr A novel in vitro three-dimensional retinoblastoma model for evaluating chemotherapeutic drugs
title_full_unstemmed A novel in vitro three-dimensional retinoblastoma model for evaluating chemotherapeutic drugs
title_short A novel in vitro three-dimensional retinoblastoma model for evaluating chemotherapeutic drugs
title_sort novel in vitro three-dimensional retinoblastoma model for evaluating chemotherapeutic drugs
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369889/
https://www.ncbi.nlm.nih.gov/pubmed/22690114
work_keys_str_mv AT mitramoutushy anovelinvitrothreedimensionalretinoblastomamodelforevaluatingchemotherapeuticdrugs
AT mohantychandana anovelinvitrothreedimensionalretinoblastomamodelforevaluatingchemotherapeuticdrugs
AT harilalanju anovelinvitrothreedimensionalretinoblastomamodelforevaluatingchemotherapeuticdrugs
AT maheswariumak anovelinvitrothreedimensionalretinoblastomamodelforevaluatingchemotherapeuticdrugs
AT sahoosanjeebkumar anovelinvitrothreedimensionalretinoblastomamodelforevaluatingchemotherapeuticdrugs
AT krishnakumarsubramanian anovelinvitrothreedimensionalretinoblastomamodelforevaluatingchemotherapeuticdrugs
AT mitramoutushy novelinvitrothreedimensionalretinoblastomamodelforevaluatingchemotherapeuticdrugs
AT mohantychandana novelinvitrothreedimensionalretinoblastomamodelforevaluatingchemotherapeuticdrugs
AT harilalanju novelinvitrothreedimensionalretinoblastomamodelforevaluatingchemotherapeuticdrugs
AT maheswariumak novelinvitrothreedimensionalretinoblastomamodelforevaluatingchemotherapeuticdrugs
AT sahoosanjeebkumar novelinvitrothreedimensionalretinoblastomamodelforevaluatingchemotherapeuticdrugs
AT krishnakumarsubramanian novelinvitrothreedimensionalretinoblastomamodelforevaluatingchemotherapeuticdrugs